Alliance Global Partners Boosts Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target to $25.00

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) had its price objective hoisted by Alliance Global Partners from $20.00 to $25.00 in a report published on Wednesday, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other brokerages have also commented on ATNM. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, July 16th. HC Wainwright lowered their price objective on shares of Actinium Pharmaceuticals from $57.00 to $45.00 and set a buy rating on the stock in a research report on Tuesday, August 3rd.

Actinium Pharmaceuticals stock opened at $7.83 on Wednesday. Actinium Pharmaceuticals has a fifty-two week low of $5.70 and a fifty-two week high of $13.18. The stock has a market capitalization of $167.02 million, a PE ratio of -4.28 and a beta of 1.03. The stock’s 50-day moving average price is $10.46.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings results on Friday, July 30th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.05. The firm had revenue of $0.27 million for the quarter. As a group, equities research analysts predict that Actinium Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Rockefeller Capital Management L.P. raised its position in shares of Actinium Pharmaceuticals by 82.0% in the first quarter. Rockefeller Capital Management L.P. now owns 6,881 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,101 shares during the period. Morgan Stanley increased its holdings in Actinium Pharmaceuticals by 368.3% during the 2nd quarter. Morgan Stanley now owns 21,489 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 16,900 shares during the period. Blair William & Co. IL bought a new stake in Actinium Pharmaceuticals during the 1st quarter worth approximately $265,000. Pinnacle Associates Ltd. bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth approximately $272,000. Finally, GSA Capital Partners LLP bought a new stake in Actinium Pharmaceuticals during the 1st quarter worth approximately $297,000. 8.01% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2002 and is headquartered in New York, NY.

Recommended Story: Most Volatile Stocks

The Fly logo

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.